Search results for "Gastrointestinal tumor"

showing 10 items of 34 documents

The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.

2020

Background Portal vein tumor thrombosis (PVTT) is a frequent complication of hepatocellular carcinoma (HCC), which leads to classification as advanced stage disease (regardless of the degree of PVTT) according to the Barcelona Clinic Liver Cancer Classification. For such patients, systemic therapy is the standard of care. However, in clinical reality, many patients with PVTT undergo different treatments, such as resection, transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), or best supportive care (BSC). Here we examined whether patients benefited from such alternative therapies, according to the extent of PVTT. Methods This analysis included therapy-naïve …

Malemedicine.medical_treatmentvirusesCancer TreatmentCardiovascular MedicineVascular MedicineDiagnostic RadiologyCohort Studies0302 clinical medicineMedical ConditionsMedicine and Health SciencesMedicineVenous ThrombosisMultidisciplinaryPortal VeinLiver DiseasesRadiology and ImagingSelective internal radiation therapyLiver NeoplasmsQRHematologyMiddle AgedTumor ResectionThrombosisMagnetic Resonance ImagingTreatment OutcomeSurgical OncologyOncologyCardiovascular Diseases030220 oncology & carcinogenesisHepatocellular carcinomaMedicine030211 gastroenterology & hepatologyFemaleRadiologyAnatomyLiver cancermedicine.drugResearch ArticleHepatic ResectionSorafenibAdultClinical Oncologymedicine.medical_specialtyCarcinoma HepatocellularImaging TechniquesScienceCardiologyRadiation TherapySurgical and Invasive Medical ProceduresGastroenterology and HepatologyResearch and Analysis MethodsVeins03 medical and health sciencesDigestive System ProceduresDiagnostic MedicineGastrointestinal TumorsHumansChemoembolization TherapeuticPortal VeinsBlood CoagulationAgedRetrospective StudiesSurgical ResectionCoagulation Disordersbusiness.industryProportional hazards modelCarcinomaCancers and NeoplasmsBiology and Life SciencesThrombosisHepatocellular Carcinomamedicine.diseaseSurvival AnalysisRadiation therapyCardiovascular AnatomyBlood VesselsClinical MedicinebusinessComplicationPLoS ONE
researchProduct

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

OncologyMaleTime FactorsDatabases FactualCancer Treatmentlcsh:MedicinePredictive Value of TestPediatricsBiochemistryGeographical locationsNeoplasms Multiple PrimaryDecision Support Technique0302 clinical medicineInterquartile rangeRetrospective StudieMultiple PrimaryRisk FactorsNeoplasmsMedicine and Health SciencesEthnicitiesPublic and Occupational HealthLiver DiseasesLiver NeoplasmsChild HealthGeneral MedicineMiddle AgedPrognosisItalian PeopleTumor BurdenQuartileOncologyCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisPredictive value of testsCohortPerspectiveHong Kong030211 gastroenterology & hepatologyFemaleSurvival Analysialpha-FetoproteinsHumanBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularAsiaTime FactorSettore MED/12 - GASTROENTEROLOGIAAged; Carcinoma Hepatocellular; Databases Factual; Decision Support Techniques; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms Multiple Primary; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Taiwan; Time Factors; Tumor Burden; alpha-Fetoproteins; Biotechnology; Biochemistry; Molecular Biology; Cell BiologyTaiwanReproducibility of ResultGastroenterology and HepatologyCarcinomasRisk AssessmentDecision Support Techniques03 medical and health sciencesDatabasesDiagnostic MedicinePredictive Value of TestsInternal medicineGastrointestinal TumorsmedicineHumansNeoplasm Invasivenessalpha-FetoproteinMolecular BiologySurvival analysisFactualAgedNeoplasm StagingRetrospective StudiesNeoplasm InvasivenePerformance statusbusiness.industryRisk Factorlcsh:RCarcinomaCancers and NeoplasmsReproducibility of ResultsRetrospective cohort studyHepatocellularHepatocellular CarcinomaCell BiologySurvival AnalysisBCLC StageSurgeryPeople and PlacesPopulation Groupingsbusiness
researchProduct

Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement

2021

An expert consensus panel convened by the Italian Association for Inherited and Familial Gastrointestinal Tumors (Associazione Italiana per lo Studio della Familiarita ed Ereditarieta dei Tumori Gastrointestinali, AIFEG) reviewed the literature and agreed on a number of position statements regarding the definition and management of polyposis coli without an identified pathogenic mutation on the APC or MUTYH genes, defined in the document as NAMP (non-APC/MUTYH polyposis).

Oncologymedicine.medical_specialtyGastrointestinal tumorsColorectal cancerSurgical ManagementColorectal polyposisGermline03 medical and health sciencesCancer Genetic0302 clinical medicineMUTYHInternal medicinemedicineCancer GeneticsPolyposis coliHepatologyPathogenic mutationbusiness.industryColorectal polyposis not associated with APC/MUTYH mutationPolyposis management guidelineGastroenterologyExpert consensusEndoscopic surveillancemedicine.diseaseColorectal cancerConsensus development conference030220 oncology & carcinogenesisCancer Genetics; Colorectal cancer; Colorectal polyposis not associated with APC/MUTYH mutation; Consensus development conference; Endoscopic surveillance; Polyposis management guideline; Surgical Management030211 gastroenterology & hepatologybusiness
researchProduct

Parathyroid hormone-related protein (PTHrP)-dependent modulation of gene expression signatures in cancer cells

2022

PTHrP is encoded by PTHLH gene which can generate by alternative promoter usage and splicing mechanisms at least three mature peptides of 139, 141 and 173 amino acids with distinct carboxy terminus. PTHrP may undergo proteolytic processing into smaller bioactive forms, comprising an amino terminus peptide, which is the mediator of the "classical" PTH-like effect, as well as midregion and carboxy terminus peptides that act as multifaceted critical regulator of proliferation, differentiation and apoptosis via the reprogramming of gene expression in normal and neoplastic cells. Moreover, a nuclear/nucleolar localization signal sequence is present in the [87-107] domain allowing PTHrP nuclear i…

Parathyroid HormoneNeoplasmsParathyroid Hormone-Related ProteinHumansApoptosisSettore BIO/06 - Anatomia Comparata E CitologiaPeptidesTranscriptomeGene signatures Bone tumor Breast tumor Gastrointestinal tumor Prostate tumor Lung cancer Leukemia/lymphoma
researchProduct

Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations

2019

Background Microsatellite instable/deficient mismatch repair (MSI/dMMR) metastatic colorectal cancers have been reported to have a poor prognosis. Frequent co-occurrence of MSI/dMMR and BRAFV600E complicates the association. Patients and methods Patients with resected stage III colon cancer (CC) from seven adjuvant studies with available data for disease recurrence and MMR and BRAFV600E status were analyzed. The primary end point was survival after recurrence (SAR). Associations of markers with SAR were analyzed using Cox proportional hazards models adjusted for age, gender, performance status, T stage, N stage, primary tumor location, grade, KRAS status, and timing of recurrence. Results A…

Proto-Oncogene Proteins B-rafdeficient mismatch repairrecurrenceBrain Neoplasmsbusiness.industryGastrointestinal tumorMicrosatellite instabilityHematologyPrognosismedicine.diseasedigestive system diseasesText miningcolon cancerOncologyNeoplastic Syndromes HereditaryColonic NeoplasmsmedicineCancer researchHumansmicrosatellite instabilityNeoplasm Recurrence LocalColorectal NeoplasmsbusinessAnnals of Oncology
researchProduct

Pterostilbene-induced tumor cytotoxicity: a lysosomal membrane permeabilization-dependent mechanism.

2012

The phenolic phytoalexin resveratrol is well known for its health-promoting and anticancer properties. Its potential benefits are, however, limited due to its low bioavailability. Pterostilbene, a natural dimethoxylated analog of resveratrol, presents higher anticancer activity than resveratrol. The mechanisms by which this polyphenol acts against cancer cells are, however, unclear. Here, we show that pterostilbene effectively inhibits cancer cell growth and stimulates apoptosis and autophagosome accumulation in cancer cells of various origins. However, these mechanisms are not determinant in cell demise. Pterostilbene promotes cancer cell death via a mechanism involving lysosomal membrane …

PterostilbeneCancer Treatmentlcsh:MedicineApoptosisResveratrolBiochemistryLung and Intrathoracic Tumorschemistry.chemical_compoundMolecular cell biologyRNA interferenceNeoplasmsPhagosomesStilbenesDrug DiscoveryBreast TumorsBasic Cancer Researchlcsh:ScienceCytotoxicitySkin TumorsApoptotic Signaling CascadeCellular Stress ResponsesMultidisciplinaryMicroscopy ConfocalCell DeathMalignant MelanomaFlow CytometryCellular StructuresSignaling CascadesCell biologyEukaryotic CellsOncologyCaspasesMedicineCellular TypesCell DivisionResearch ArticleSignal TransductionProgrammed cell deathDrugs and DevicesDrug Research and DevelopmentMitosisAntineoplastic AgentsBiologyPermeabilityCell GrowthInhibitory Concentration 50NecrosisComplementary and Alternative MedicineCell Line TumorGastrointestinal TumorsAutophagyHumansHSP70 Heat-Shock ProteinsBiologyCell ProliferationDose-Response Relationship DrugL-Lactate DehydrogenaseCell growthlcsh:RAutophagyProteinsCancers and NeoplasmsRegulatory ProteinschemistrySubcellular OrganellesApoptosisResveratrolCancer celllcsh:QGene expressionLysosomesCytometryPloS one
researchProduct

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

2020

Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC an…

RNA virusesMaleEtiologyCancer TreatmentHepacivirusKaplan-Meier EstimateBiochemistryCohort StudiesWhite Blood CellsMathematical and Statistical TechniquesRetrospective StudieAnimal CellsAdult; Aged; Aged 80 and over; Antineoplastic Agents; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies; Serum Albumin; Sorafenib; Nutrition AssessmentMedicine and Health Sciences80 and overLymphocytesPathology and laboratory medicineAged 80 and overHepatitis C virusLiver DiseasesStatisticsQLiver NeoplasmsRMedical microbiologyMiddle AgedSorafenibPrognosisOncologyItalyLiver NeoplasmPhysical SciencesVirusesMedicineFemalePathogensCellular TypesHumanResearch ArticleAdultHepatitis B virusCarcinoma HepatocellularImmune CellsScienceImmunologyAntineoplastic AgentsGastroenterology and HepatologySerum Albumin ...Research and Analysis MethodsCarcinomasMicrobiologyAlbuminsGastrointestinal TumorsHumansLymphocyte CountStatistical MethodsSerum AlbuminAgedRetrospective StudiesBlood CellsAdult Aged 80 and over Antineoplastic Agents Carcinoma Hepatocellular Cohort Studies Female Humans Italy Kaplan-Meier Estimate Liver Neoplasms Lymphocyte Count Male Middle Aged Prognosis Retrospective Studies Serum Albumin Sorafenib Nutrition AssessmentBiology and life sciencesFlavivirusesCarcinomaViral pathogensOrganismsCancers and NeoplasmsProteinsHepatocellularHepatocellular CarcinomaCell Biologyprognostic nutritional index (PNI) hepatocellular carcinoma (HCC) sorafenib. survival mRECISTHepatitis virusesMicrobial pathogensNutrition AssessmentMultivariate AnalysisCohort StudieMathematics
researchProduct

Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors

2008

To review the implication of CXCR4 for gastrointestinal cancer, a "Pubmed" analysis was performed in order to evaluate the relevance of CXCR4 and its ligands for gastrointestinal cancers. Search terms applied were "cancer, malignoma, esophageal, gastric, colon, colorectal, hepatic, pancreatic, CXCR4, SDF-1alpha, and SDF-1beta". CXCR4 expression correlated with dissemination of diverse gastrointestinal malignomas. The CXCR4 ligand SDF-1alpha might act as "chemorepellent" while SDF-1beta might act as "chemorepellent" for CTLs, inducing tumor rejection. The paracrine expression of SDF-1alpha was furthermore closely associated with neoangiogenesis. CXCR4 and its ligands influence the disseminat…

Receptors CXCR4Prognostic factorGastrointestinal tumorsBiologyLigandsCXCR4Paracrine signallingChemokine receptorBiomarkers TumormedicineAnimalsHumansNeoplasm InvasivenessGastrointestinal cancerNeoplasm MetastasisGastrointestinal NeoplasmsGastroenterologyCancerGeneral Medicinemedicine.diseaseChemokine CXCL12EditorialTreatment OutcomeSearch termsImmunologyCancer researchWorld Journal of Gastroenterology
researchProduct

The role of targeted therapy for gastrointestinal tumors

2014

Abstract: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinic…

SorafenibOncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyReceptor ErbB-2Hepatocellular carcinomaSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsNeuroendocrine tumorsTargeted therapyTargeted therapychemistry.chemical_compoundNeuroendocrine tumorTrastuzumabInternal medicineRegorafenibmedicineHumansGastrointestinal tumorsMolecular Targeted TherapyProtein Kinase InhibitorsGastrointestinal NeoplasmsEverolimusHepatologySunitinibbusiness.industryColorectal cancer; Gastric cancer; Gastrointestinal tumors; Hepatocellular carcinoma; Neuroendocrine tumors; Targeted therapy; Hepatology; GastroenterologyGastrointestinal tumorGastroenterologyCancermedicine.diseaseColorectal cancerErbB ReceptorsReceptors Vascular Endothelial Growth FactorchemistryHuman medicineNeuroendocrine tumorsbusinessGastric cancermedicine.drug
researchProduct

Gastrointestinal tumors: Phytochemical and drug combinations targeting the hallmarks of cancer

2021

Cancer is a worldwide burden resulting in millions of deaths each year. In particular, gastrointestinal tumors are life-threatening malignancies and one of the leading reasons for death in developed countries. Phytochemicals can be found in grains, vegetables, fruits and several foods. Many phytochemicals, such as curcumin, genistein, luteolin, vitexin-2-O-xyloside, avenanthramides, quercetin, epigallocatechin-3-gallate (EGCG), resveratrol, sulforaphane, piperine and thymoquinone have been used in combination with different chemotherapeutic agents for their synergistic anticancer effects against various forms of cancer. In this review, we describe the antitumor properties and biological eff…

TechnologyColorectal cancerQH301-705.5oncogenesQC1-999gastrointestinal tumorsPhytochemicalsHallmarks of cancerchemistry.chemical_compoundPancreatic cancermedicineGeneral Materials ScienceBiology (General)InstrumentationQD1-999ThymoquinoneOncogeneFluid Flow and Transfer Processesbusiness.industryProcess Chemistry and TechnologyTPhysicsGeneral EngineeringGastrointestinal tumorCancerAnticancer drugmedicine.diseaseEngineering (General). Civil engineering (General)phytochemicalsComputer Science ApplicationsChemistryanticancer drugsThe Hallmarks of CancerchemistryPhytochemicalCancer researchTA1-2040Liver cancerbusinesshallmarks of cancer; oncogenes; phytochemicals; anticancer drugs; gastrointestinal tumorshallmarks of cancerSulforaphane
researchProduct